Literature DB >> 8450670

Minimally differentiated acute leukemia.

F J Cadwell1, C P Burns, F R Dick, M P Jones, K D Heckman, G J Weiner, J A Goeken.   

Abstract

We have studied 35 adult patients with morphologically undifferentiated peroxidase-negative acute leukemia that failed to meet the criteria for acute lymphoblastic leukemia and compared them to patients with FAB M1-M7 seen by the same physicians. The diagnosis of minimally differentiated acute leukemia (MD-AL) was associated with a higher incidence of prior hematologic disease, lower WBC, fewer blood blasts, lower marrow cellularity and a tendency towards older age. Of all patients treated with AML since January 1983, those with MD-AL were less likely to get a complete remission than those with other subtypes (35 vs 64%, p = 0.03). Treatment failure was usually due to resistant disease. Analysis of outcome as a function of drugs used during induction therapy showed an advantage for regimens containing vincristine and prednisone. The leukemic blast cells of nine patients were immunophenotyped for myeloid, lymphoid and megakaryoblast/platelet antigens. Although there were too few for a full statistical analysis as was applied to the larger group of 35 patients with MD-AL, these patients had a lower bone marrow cellularity as compared to FAB M1-M7 and a low remission rate. Eight of these were found to have positive myeloid markers and met the criteria for FAB M0. We conclude that patients with MD-AL form a distinct group with characteristic presenting features and a low response rate. Outcome data suggest that vincristine and prednisone should be included in experimental induction programs.

Entities:  

Mesh:

Year:  1993        PMID: 8450670     DOI: 10.1016/0145-2126(93)90002-3

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  1 in total

1.  Prognostic significance of CD7+CD56+ phenotype and chromosome 5 abnormalities for acute myeloid leukemia M0.

Authors:  Ritsuro Suzuki; Makoto Murata; Masahiro Kami; Shigeki Ohtake; Norio Asou; Yoshihisa Kodera; Masao Tomonaga; Yasufumi Masaki; Shuya Kusumoto; Jin Takeuchi; Shin Matsuda; Hisamaru Hirai; m Seiichi Yorimitsu; Nobuyuki Hamajima; Masao Seto; Masanori Shimoyama; Ryuzo Ohno; Yasuo Morishima; Shigeo Nakamura
Journal:  Int J Hematol       Date:  2003-06       Impact factor: 2.490

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.